AU2019335968B2 - Heterocyclic compound - Google Patents

Heterocyclic compound Download PDF

Info

Publication number
AU2019335968B2
AU2019335968B2 AU2019335968A AU2019335968A AU2019335968B2 AU 2019335968 B2 AU2019335968 B2 AU 2019335968B2 AU 2019335968 A AU2019335968 A AU 2019335968A AU 2019335968 A AU2019335968 A AU 2019335968A AU 2019335968 B2 AU2019335968 B2 AU 2019335968B2
Authority
AU
Australia
Prior art keywords
mhz
nmr1
ring
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019335968A
Other languages
English (en)
Other versions
AU2019335968A1 (en
Inventor
Yusuke FUJIMORI
Hideki Hayashi
Noritaka Koseki
Naoya MAKITA
Kurumi MINENO
Kazuhiro OHDACHI
Yuki Sakamoto
Ryosuke TAGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2019335968A1 publication Critical patent/AU2019335968A1/en
Application granted granted Critical
Publication of AU2019335968B2 publication Critical patent/AU2019335968B2/en
Priority to AU2024203760A priority Critical patent/AU2024203760A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2019335968A 2018-09-07 2019-09-06 Heterocyclic compound Active AU2019335968B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203760A AU2024203760A1 (en) 2018-09-07 2024-06-04 Heterocyclic compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-167488 2018-09-07
JP2018167488 2018-09-07
PCT/JP2019/035233 WO2020050409A1 (en) 2018-09-07 2019-09-06 Heterocyclic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203760A Division AU2024203760A1 (en) 2018-09-07 2024-06-04 Heterocyclic compound

Publications (2)

Publication Number Publication Date
AU2019335968A1 AU2019335968A1 (en) 2021-05-06
AU2019335968B2 true AU2019335968B2 (en) 2024-03-07

Family

ID=68063002

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019335968A Active AU2019335968B2 (en) 2018-09-07 2019-09-06 Heterocyclic compound
AU2024203760A Pending AU2024203760A1 (en) 2018-09-07 2024-06-04 Heterocyclic compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203760A Pending AU2024203760A1 (en) 2018-09-07 2024-06-04 Heterocyclic compound

Country Status (12)

Country Link
US (2) US11932657B2 (https=)
EP (1) EP3847176A1 (https=)
JP (1) JP7448527B2 (https=)
KR (1) KR102810086B1 (https=)
CN (1) CN112654627A (https=)
AU (2) AU2019335968B2 (https=)
CA (1) CA3109610A1 (https=)
EA (1) EA202190654A1 (https=)
IL (1) IL280821B2 (https=)
SG (1) SG11202101963XA (https=)
TW (1) TWI854995B (https=)
WO (1) WO2020050409A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
KR20240054994A (ko) * 2021-09-02 2024-04-26 재규어 테라퓨틱스 피티이 리미티드 AhR 시그널링의 조절에 유용한 화합물
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
JP7527515B1 (ja) * 2022-10-29 2024-08-02 松本油脂製薬株式会社 弾性繊維用処理剤及びその利用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
DK3312270T3 (da) 2015-06-16 2020-10-12 Univ Kyoto Fremgangsmåde til fremstilling af plader med høj ydeevne
WO2018195397A2 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
WO2019167973A1 (en) 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
IL291322B2 (en) 2019-12-09 2026-02-01 Otsuka Pharma Co Ltd Acrylamide compounds
JP2022188761A (ja) 2021-06-09 2022-12-21 大塚製薬株式会社 窒素原子含有複素環化合物を用いる血小板産生方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Also Published As

Publication number Publication date
AU2019335968A1 (en) 2021-05-06
US20210340157A1 (en) 2021-11-04
CN112654627A (zh) 2021-04-13
WO2020050409A1 (en) 2020-03-12
CA3109610A1 (en) 2020-03-12
IL280821B1 (en) 2024-10-01
EA202190654A1 (ru) 2021-05-27
KR102810086B1 (ko) 2025-05-21
IL280821B2 (en) 2025-02-01
US11932657B2 (en) 2024-03-19
SG11202101963XA (en) 2021-03-30
NZ774547A (en) 2025-10-31
EP3847176A1 (en) 2021-07-14
US20240208999A1 (en) 2024-06-27
TW202035423A (zh) 2020-10-01
JP7448527B2 (ja) 2024-03-12
TWI854995B (zh) 2024-09-11
JP2021536482A (ja) 2021-12-27
AU2024203760A1 (en) 2024-06-20
KR20210056373A (ko) 2021-05-18
IL280821A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
AU2019335968B2 (en) Heterocyclic compound
CN101835764B (zh) 唑甲酰胺化合物或其盐
AU2002219555B2 (en) VLA-4 Inhibitors
JP3614865B2 (ja) 新規な環状ジアミン化合物及びこれを含有する医薬
TWI440639B (zh) 作為trpv1調節劑之四氫-嘧啶并氮呯類
TWI836960B (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
TW201839000A (zh) 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
CA2735730A1 (en) 2,4-diaminopyrimidine compound
CA2793856A1 (en) Tetrahydrobenzothiophene compound
CN106458940A (zh) 人类免疫缺陷病毒复制的抑制剂
JP2016510781A (ja) RORcモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体
WO2009085256A1 (en) Anti-hiv compounds
CA2761853A1 (en) Benzoxazolone derivatives as aldosterone synthase inhibitors
CA2862698A1 (en) Azaheterocyclic compounds
JP2016502987A (ja) RORcモジュレーターとしてのベンジルスルホンアミド誘導体
JP5201817B2 (ja) 医薬組成物
KR20180040560A (ko) Ror 감마 (rory) 조정제
WO2010102154A2 (en) Biaryl oxyacetic acid compounds
CN112469714B (zh) 作为端锚聚合酶抑制剂的1,2,4-三唑衍生物
CA3155466A1 (en) Acrylamide compounds
WO2004112709A2 (en) Inhibitors of cathepsin s
EA046483B1 (ru) Гетероциклическое соединение
HK40048052A (zh) 杂环化合物
AU2013351550A1 (en) Specific carboxamides as KCNQ2/3 modulators
HK40086122A (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers